Lejie Cao

机构：University of Science and Technology of China, Anhui Provincial Hospital

发表论文 67 篇 · 总被引 2946 次 · h-index 24

代表论文

• Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer (2024 · JAMA · 被引 361)
• Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial (2023 · EClinicalMedicine · 被引 54)
• Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC (2023 · Nature Cancer · 被引 34)
• Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial (2023 · Signal Transduction and Targeted Therapy · 被引 32)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 27)
• Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial (2023 · Signal Transduction and Targeted Therapy · 被引 18)